Both antimicrobial resistance and pandemics are highly complex issues and serious threats to global public health and the world economy. Yet, many industrial partners including pharmaceutical companies have withdrawn from research and development for tackling antibiotic resistance and pandemics given the scientific challenges associated with the development of novel antibiotics, the economic and regulatory challenges to ensure access to novel drugs and products and intermittent funding for R&D that disappears soon after epidemics are over.

There is a need to explore push and pull incentives for R&D to tackle antibiotic resistance and pandemics and ensuring continued engagement of relevant stakeholders including the biopharmaceutical sector in addition to exploring the role of the G20 governments in incentivising R&D.

This panel will discuss the push and pull incentives for the relevant stakeholders including the biopharmaceutical sector to sustain efforts for combating AMR and pandemics.